Thoracentesis
A procedure to remove fluid from around the lungs, providing immediate relief from breathlessness and discomfort.
Palliative ProcedureOverview
Thoracentesis (also called pleural tap) is a procedure to drain fluid that has accumulated between the lung and chest wall (pleural effusion). For mesothelioma patients, this is often one of the first procedures performed, both for diagnosis and symptom relief.
Who May Be a Candidate
- Patients with pleural effusion causing symptoms
- Diagnostic evaluation of pleural fluid
- Those needing quick symptom relief
- Patients too ill for more invasive procedures
How It Works
A needle is inserted through the chest wall into the pleural space, and fluid is drained using a syringe or vacuum bottle. The procedure is usually guided by ultrasound for safety.
Procedure Steps
- Local anesthetic applied to chest wall
- Ultrasound used to locate fluid
- Needle inserted between ribs into pleural space
- Fluid drained (usually 1-1.5 liters maximum)
- Needle removed and bandage applied
- Fluid sent for analysis
Benefits
- Immediate relief from breathlessness
- Provides fluid for diagnostic testing
- Minimally invasive
- Can be performed at bedside or outpatient
- Low risk procedure
Risks & Side Effects
- Pneumothorax (collapsed lung)
- Bleeding
- Infection
- Re-expansion pulmonary edema (rare)
- Fluid typically reaccumulates
Recovery
No significant recovery time needed. Patients often feel immediate improvement in breathing. Can resume normal activities same day. Chest X-ray may be performed afterward to check for complications.
Expected Outcomes
Provides quick symptom relief but does not treat the underlying disease. Fluid typically reaccumulates within weeks to months, requiring repeat procedures or pleurodesis.
Finding Treatment
This procedure is typically performed at specialized mesothelioma treatment centers with experienced surgical teams. Consulting with a mesothelioma specialist is the first step in determining if this treatment is appropriate for your situation.
Treatment Q&A
Frequently Asked Questions
How fast does pleural mesothelioma progress?
Pleural mesothelioma often has a long latency period, with symptoms usually appearing 20 to 50 years after asbestos exposure, but the cancer can progress quickly once it is diagnosed. Published sources note that untreated pleural mesothelioma has had median survival under a year, while first-line nivolumab plus ipilimumab in the CheckMate-743 trial was linked to a median overall survival of 18.1 months versus 14.1 months with chemotherapy. Progression is highly variable and depends on histology, stage, and overall health, so some people decline over weeks or months, while others live for several years.
How long do you stay in hospital for thoracentesis?
Most people having a standard thoracentesis as a planned procedure go home the same day, often within a few hours after brief observation and a follow‑up chest X‑ray. Sources such as Cleveland Clinic note that the procedure itself typically takes about 15 minutes, with short recovery times. Some hospitals advise limiting activity for the rest of the day and for 24 to 48 hours overall, but not staying overnight. If a catheter or chest tube is left in place to keep draining fluid, people may stay in the hospital 1 to 2 days until it is removed. The exact length of stay varies based on the person’s overall condition, how much fluid is removed, and whether complications such as low blood pressure or pneumothorax occur.
What is the best treatment for pleural mesothelioma?
Evidence from major cancer centers and recent ASCO guidelines shows there is no single “best” treatment for pleural mesothelioma, because outcomes depend heavily on stage, cell type, overall health, and whether tumors can be removed with surgery. For people with resectable disease, multimodal therapy that combines surgery (such as pleurectomy and decortication or extrapleural pneumonectomy) with chemotherapy, radiation, and sometimes immunotherapy is associated with the longest survival in published studies. For unresectable pleural mesothelioma, first-line systemic treatment now commonly involves immunotherapy with nivolumab plus ipilimumab or chemoimmunotherapy such as pembrolizumab with pemetrexed and a platinum drug, which in trials improved 2-year survival compared with chemotherapy alone. Chemotherapy with pemetrexed and cisplatin or carboplatin remains a core option across stages, and palliative procedures (like draining chest fluid, pleurodesis, or targeted radiation) play a key role in symptom relief and quality of life. People with mesothelioma are often encouraged in the medical literature to consider clinical trials, since ongoing studies are testing newer immunotherapies, targeted drugs, and advanced radiation or surgical techniques.
What is the most common complication after a thoracentesis?
The most common complication after thoracentesis is pneumothorax, which is air leaking into the pleural space that can partially or fully collapse a lung. Historical reports described pneumothorax rates as high as 19%, but more recent studies that use routine ultrasound guidance show lower rates around 2% to 6%. Large-volume fluid removal, multiple needle passes, and very low body weight are reported risk factors that increase the chance of pneumothorax.